 | | Vol. 4.30 – 3 September, 2020 |
| |
|
|
| Hypoxia induced increased fibroblast growth factor receptor 1 (FGFR1) expression in NSCLC cell lines H1975, HCC827 and YLR086, and knockdown of FGFR1 attenuated hypoxia-induced epidermal growth factor receptor tyrosine kinase inhibitors resistance in each line.
[Cancer Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors found that gliotoxin (GT) was more cytotoxic to lung epithelial cells than fumagillin (FUM), and that GT and FUM acted synergistically to inflict pathology to lung epithelial cells.
[Scientific Reports] |
|
|
|
| Alveolar epithelial type II cells (AE2) of young mice adapted to injury by increasing intracellular surfactant volume and proliferation rate. In old mice, however, this adaptive response was compromised and AE2 of old mice showed signs of cell senescence, increased inflammatory signaling and impaired surfactant metabolism in acute lung injury.
[American Journal of Physiology-Lung Cellular and Molecular Physiology] |
|
|
|
| To investigate how high mobility group box 1 (HMGB1) affects the barrier of normal human lung epithelial cells, monolayer cells and bronchial-like spheroid cells, which have lumen formation, were pretreated with TGF-β type I receptor kinase inhibitor EW-7197 before treatment with HMGB1.
[Tissue Barriers] |
| |
|
|
| Researchers revealed the oncogenic roles of LINC00301 in clinical specimens as well as cellular and animal experiments, illustrating the potential roles and mechanisms of the FOXC1/LINC00301/EZH2/EAF2/pVHL/HIF1α and FOXC1/LINC00301/miR-1276/HIF1α pathways.
[Genome Medicine] |
|
|
|
| In NSCLC cell lines, H3K4me3 but not H3K27me2/3 or H3K4me1/2 was markedly altered upon KDM6A or KMT2B knockdown, indicating that KDM6A may act independently of H3K27 demethylases in NSCLC.
[Oncogene] |
|
|
|
| NSCLC cells were pre-treated with mitomycin C (MMC) and then co-cultured with peripheral blood mononuclear cells to investigate the effect of the combination of MMC with PD-L1 antibody.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Overexpression of miR-3614-5p attenuated non-small-cell lung cancer cell proliferation and invasion, and these effects could be partially reversed by reintroduction of phosphoglycerate mutase 1.
[Cell Death & Disease] |
|
|
|
| Scientists report that squalene synthase induced the phosphorylation of Src and ERK1/2 via osteopontin, resulting in increased expression of MMP1 and subsequent metastasis of lung cancer cells. Based on their research, squalene synthase expression increased the expression of osteopontin and phosphorylation of Src through cholesterol synthesis to modulate the formation of lipid rafts.
[Oncogenesis] |
|
|
|
| Investigators found that LAMP2A knockdown in NSCLC cells suppressed cell proliferation and colony formation, and increased the sensitivity to chemotherapeutic drugs in vitro. They also found that intrinsic apoptosis signaling was the mechanism of cell death involved with chaperone‐mediated autophagy blockade.
[Cancer Science] |
|
|
|
|
| Alveolar type 2 (AT2) cells and other distal lung epithelia contain an elegant quality control (QC) network to respond to intrinsic metabolic and biosynthetic challenges imparted by mutant protein conformers, dysfunctional subcellular organelles, and dysregulated telomeres. Failed AT2 QC components result in diverse cellular endophenotypes and molecular signatures that ultimately converge to drive downstream fibrotic remodeling in the idiopathic pulmonary fibrosis lung.
[Journal of Clinical Investigation] |
|
|
|
|
| Addario Lung Cancer Medical Institute and Biodesix, Inc. announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including the proteomic Primary Immune Response test, for front-line NSCLC patients receiving immunotherapy with and without the addition of systemic platinum-based chemotherapy who have high expression of program death ligand-1 on their tumor cells.
[Biodesix, Inc.] |
|
|
|
| Bicycle Therapeutics announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK. The trial is evaluating BT1718 in patients with MT1-MMP-positive squamous NSCLC and a basket of other MT1-MMP-positive solid tumors.
[Bicycle Therapeutics] |
|
|
|
|
|
|
|
| | The University of Southern California – Los Angeles, California, United States |
|
|
|
| | NYU Langone Health – New York, New York, United States |
|
|
|
| | Institut Mondor de Recherche Biomédicale (IMRB) – Creteil, France |
|
|
|
| | Institute for Computational Medicine – Baltimore, Maryland, United States |
|
|
|
| | National Heart and Lung Institute – London, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
